Prevalence of Hematotoxic Effect of Intravenous Chemotherapy among Retinoblastoma Population in Tertiary Hospital in Bandung, Indonesia

Jennifer Hadiman; Susi Susanah; Adhi Kristianto Sugianli

doi:10.15850/ijihs.v7n1.1520

Prevalence of Hematotoxic Effect of Intravenous Chemotherapy among Retinoblastoma Population in Tertiary Hospital in Bandung, Indonesia

Jennifer Hadiman, Susi Susanah, Adhi Kristianto Sugianli

Abstract

Objective: To observe the prevalence of hematotoxic effect in retinoblastoma patients who were given intravenous chemotherapy with vincristine, etoposide, and carboplatin (VEC) regimen. Retinoblastoma is the second most common cancer in children in Indonesia. Standard chemotherapy agents used in retinoblastoma treatment is VEC given in 7 cycles intravenously. The most common side effect of VEC regimen is hematotoxic effect which might lead to chemotherapy failure.

Methods: This study used descriptive method with cross sectional study design. Data were collected from medical records of retinoblastoma patients in Dr. Hasan Sadikin General Hospital Bandung, Indonesia, from 2014 until 2016 using total sampling technique.

Results: Forty-six patients were included in this study. Of those subjects, 36 (78.3%) patients experienced hematotoxic effect. The most common hematotoxic effect occurred were anemia and neutropenia, that occurred in 32 (69.6%) and 18 (39.1%) patients, respectively. The most common hematotoxic effect severity occurred were grade 1 anemia, grade 1 leukopenia, grade 1 neutropenia, and grade 3 thrombocytopenia. Percentage of patients experienced anemia tended to increase until the 7th cycle. Seven (15.2%) patients had anemia prior to chemotherapy administration.

Conclusion: The majority (78.3%) of the patients experienced hematotoxic effect on intravenous chemotherapy administration with VEC regimen. Anemia was the most common hematotoxic effect occurred.

Keywords: Hematotoxic effect, intravenous chemotherapy, retinoblastoma

Keywords

Hematotoxic effect, intravenous chemotherapy, retinoblastoma

Full Text:

PDF

References

Kementerian Kesehatan Republik Indonesia. Pedoman penemuan dini kanker pada anak: Jakarta: Kementerian Kesehatan Republik Indonesia; 2011.

Ghassemi F, Khodabande A. Risk definition and management strategies in retinoblastoma: current perspectives. Clin Ophthalmol. 2015;9(3):985–94.

Mendoza PR, Grossniklaus HE. Therapeutic Options for Retinoblastoma. Cancer Control. 2016;23(2):99–109.

Yanik Ö, Gündüz K, Yavuz K, Taçyıldız N, Ünal E. Chemotherapy in retinoblastoma: current approaches. Turk J Ophthalmol. 2015;45(6):259–67.

Sherley JL. Human stem cell toxicology. Cambridge: The Royal Society of Chemistry; 2016.

Papież MA. The effect of quercetin on oxidative DNA damage and myelosuppression induced by etoposide in bone marrow cells of rats. Acta Biochimica Polonica. 2014;61(1):7–11.

Busti F, Marchi G, Ugolini S, Castagna A, Gerelli D. Anemia and iron deficiency in cancer patients: role of iron replacement therapy. Pharmaceuticals.2018;11(94):1–14.

Brigle K, Pierre A, Oliver EF, Faiman B, Tariman JD, Miceli T, et al. Myelosuppression, bone disease, and acute renal failure. Clin J Oncol Nurs. 2018;21(5):60–76.

World Health Organization. WHO multicentre growth reference study group. Geneva: World Health Organization; 2006.

World Health Organization. Guidelines for monitoring and reporting adverse events drug reactions 2013. [cited 2018 Dec 6]. Available from: https://apps.who.int/medicinedocs/documents/s18571en/s18571en.pdf.

Soebagjo HD, Prastyani R, Sujuti H, Lyrawati D, Sumitro SB. Profile of retinoblastoma in East Java, Indonesia. World J Med Med Sci Res. 2013;1(3):51–6.

Subha L, Reddy AS, Ramyaa. A clinical study of retinoblastoma. J Pharm Bioallied Sci. 2015;7(Suppl 1):S2–S3.

Choi S, Han JW, Kim H, Kim BS, Kim DJ, Lee SC, et al. Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma. Korean J Pediatr. 2013;56(6):254–9.

Qaddoumi I, Billups CA, Tagen M, Stewart CF, Wu J, Helton K, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer. 2012;118(22):5663–70.

Caubet M, Dobi E, Pozet A, Almotlak H, Montcuquet P, Maurina T et al. Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study. Molecular and Clinical Oncology. 2015;3(6):1208–12.

Chu E, DeVita VT. Physicians’ Cancer chemotherapy drug manual. Massachusetts: Jones & Bartlett Learning; 2015.

Chen X, Wang J, Fu Z, Zhu B, Wang J, Guan S, et al. Curcumin activates DNA repair pathway in bone marrow to improve carboplatin-induced myelosuppression. Sci Reprt. 2017;7(1):1–11.

Doleschel D, Rix A, Arns S, Palmowski K, Gremse F, Markle R, et al. Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion. Theranostics. 2015;5(8):905–18.

Xu H, Xu L, Page JH, Cannavale K, Sattayapiwat O, Rodriguez R, et al. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy. Clin Epidemiol. 2016;8(1):61–71.

Sullivan EM, Wilson MW, Billups CA, Wu J, Merchant TE, Brennan RC, et al. Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol. 2014;36(6):335–40.

DOI: https://doi.org/10.15850/ijihs.v7n1.1520